Home Medical OncologyQuestion

Do we need to continue dose escalations wtih DA REPOCH after a negative interim PET scan for PMBCL?

Join the Discussion

Discuss the cases and questions guidelines don't cover.

Related Questions

How would you approach adjusting nivo+AVD therapy for advanced Hodgkin lymphoma if a patient develops treatment limited immunotherapy toxicity?

In light of data from TRIANGLE, ECHO, and ENRICH, what is the best strategy to treat newly diagnosed patients with the blastoid variant MCL?

How would you manage a patient with a recent diagnosis of advanced DLBCL (non-GCB subtype) who has baseline grade 3 neuropathy?

Has the data for the ENRICH study changed your practice for the initial treatment of mantle-cell lymphoma?

How would you manage a patient with DLBCL that progressed on/after EPOCH and subsequently treated with a CD19 allo CAR-T product within 90 days of receiving apheresis?

Evidence Meets Expertise

For Physicians

Mednet AI
Community

Company

About
Careers
Publications
Blog

Support

FAQs
Code of Conduct
AI Community Guidelines
Contact Us
Programs

Legal

Privacy Policy
Terms of Service

© 2026 Mednet Inc. All rights reserved.